Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Recent Videos
Related Content
Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

Martin David Harp
March 25th 2025
Article
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes

Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes

Lynda Charters
March 19th 2025
Article
The future of retina: New targets and more durable solutions

The future of retina: New targets and more durable solutions

Robin Vora, MD;Hannah El-Sabrout
March 18th 2025
Article
4DMT enrolls first patient in phase 3 4FRONT-1 evaluating 4D-150 for the treatment of wet AMD

4DMT enrolls first patient in phase 3 4FRONT-1 evaluating 4D-150 for the treatment of wet AMD

Martin David Harp
March 11th 2025
Article
Data from Phase 1/2a clinical trial evaluating RPESC-RPE-4W presented at 77th Annual Wills Eye Conference

Data from Phase 1/2a clinical trial evaluating RPESC-RPE-4W presented at 77th Annual Wills Eye Conference

Sydney M Crago
March 8th 2025
Article
PER launches Retina Resource, a comprehensive anti-VEGF education and information tool

PER launches Retina Resource, a comprehensive anti-VEGF education and information tool

Sydney M Crago
March 7th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.